Despite being the recommended treatment, PPCI is underutilized in Europe (40-45% of STEMI patients), highlighting the need to understand and address complex implementation barriers.
Answers are grounded in this paper and cite their sources.
PPCI remains underused for European STEMI despite guideline endorsement; leaves open identification of country-level barriers and implementation strategies.
Primary percutaneous coronary intervention (PPCI) is the recommended treatment for patients with acute ST-segment elevation myocardial infarction (STEMI). Despite substantial evidence of its effectiveness, only 40–45% of European STEMI patients are currently treated with PPCI and there are large differences in this proportion between different European countries. Several studies have emphasised that PPCI delivery is complex, with multiple potential barriers to implementation, but there is no comprehensive research estimating the significant characteristics, factors and structures that determine the diffusion of PPCI in Europe. The lack of complete implementation and large national and regional differences arise from the interplay between technology, patients, policy makers, culture and resources. Explanations for the variation in treatment access still remain a puzzle and access to valid data is needed.
No takes yet. Share an insight, caveat, or question.
Laut et al. (2011) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: